Kisspeptin reaches a training audience through the testosterone conversation: it sits upstream of the hormonal cascade that ends in LH, and LH drives testicular testosterone production. The inference people draw from that is understandable and the evidence behind it is not what they assume.
The research base is genuinely strong
ClinicalTrials.gov lists roughly 45 studies under the name. Four are Phase 3, nine Phase 2, eleven Phase 1, and around 26 are marked completed. The sponsor list is academic: a named investigator and Massachusetts General Hospital account for the largest share, with Imperial College London and university hospitals elsewhere adding more.
Set that against the compounds usually discussed on this site. MOTS-c has no genuine registered trial. BPC-157 has two Phase 1 records, neither reported. Kisspeptin has a completed academic programme and several thousand PubMed records.
What the trials were measuring
The work is reproductive endocrinology. Kisspeptin signals through its receptor to drive GnRH release, and downstream of that, luteinising hormone. The clinical questions follow from that mechanism: delayed puberty, hypogonadotropic hypogonadism, fertility, and use as a trigger in assisted reproduction.
Quantities used in those studies were selected to produce a measurable hormonal response in a defined patient group, under supervision, with assays reading the result. That is a dosing context, and it is not a body composition one.
The inference that does not hold
Raising LH acutely in a clinical protocol is not the same claim as improving body composition or lean mass in a trained adult. No trial in that programme was designed to test the second, and a hormonal response measured over hours says nothing about tissue outcomes over months.
Nothing here rules that use out. It simply has not been studied, and the strength of the reproductive literature does not transfer to it.
Reading a chart for it
A kisspeptin dosage chart has better raw material than most: published human studies rather than rodent figures needing a species conversion. It also has a specific failure mode, which is presenting clinical quantities without the population and endpoint they belong to.
No regulator has approved the compound as a marketed medicine, so no authorised dose exists. A trial programme and a label are different things, and only one of them sets a number anybody is accountable for.